PT  - JOURNAL ARTICLE
AU  - BRINCK, ULRICH
AU  - SCHLOTT, THILO
AU  - STÖRBER, STEFFI
AU  - STACHURA, JERZY
AU  - BORTKIEWICZ, PAWEL
AU  - NAGEL, WOLF-DIETER
AU  - HASSE, FRANK MICHAEL
AU  - CORDON-CARDO, CARLOS
AU  - FISCHER, GÖSTA
AU  - KORABIOWSKA, MONIKA
TI  - Alterations of the Retinoblastoma and P16 Pathway Correlate with Promoter Methylation in Malignant Fibrous Histiocytomas
DP  - 2006 Sep 01
TA  - Anticancer Research
PG  - 3461--3465
VI  - 26
IP  - 5A
4099  - http://ar.iiarjournals.org/content/26/5A/3461.short
4100  - http://ar.iiarjournals.org/content/26/5A/3461.full
SO  - Anticancer Res2006 Sep 01; 26
AB  - Recent reports indicate that the alterations in the p16 and pRb pathways can influence tumour progression and poor prognosis in several tumours. The objective of this study was to analyse p16 and pRb expression in161 patients with malignant fibrous histiocytomas (MFH). By immunohistochemistry, p16 and pRb were demonstrated in 25% and 56% of MFH, respectively. Cox regression analysis demonstrated an independent prognostic influence of both genes. Generally, the loss of p16 and pRb expression correlated with poorer prognosis. Promoter methylation of p16 was found in 16/42 of p16 negative MFH and of pRb in 2/42 of pRb-negative MFH. It can be concluded that p16 and pRb alterations play an important role in the progression of soft tissue sarcomas. Copyright© 2006 International Institute of Anticancer Research (Dr. John G. Delinassios), All rights reserved